Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CD Taxanes
L01CD04 Cabazitaxel
D10452 Cabazitaxel acetonate (JAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Cabazitaxel
D10452 Cabazitaxel acetonate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
424 Plant extract preparations
4240 Plant extract preparations
D10452 Cabazitaxel acetonate (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00695 Cabazitaxel
D10452 Cabazitaxel acetonate
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D10452 Cabazitaxel acetonate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10452
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10452
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10452
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10452
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10452
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00695 Cabazitaxel